U.S. Dr Wick Bright, a former whistleblower at Health and Human Services, said on Thursday that data from the drug Covid-1 showed that there were only minor benefits and that it was not a ‘home run’.
U.S. The Food and Drug Administration on Thursday approved rimadesivir for the treatment of Kovid-19 patients hospitalized – the first drug approved for coronavirus.
Bright said it’s not an effective drug.
“It’s important to note that the data we saw from that drug in the United States also showed that the benefit was modest,” Bright told CNN’s Wolf Blitzer. “It simply came to our notice then. It was not a significant improvement in terms of mortality, nor did it show a slight advantage in lengthening or shortening the length of hospital stay. “
A global study sponsored by the World Health Organization found that remedesivir did not help Covid-19 patients survive or recover quickly.
“The FDA has explicitly reviewed all available data from the company to review the effectiveness and safety of that drug,” Bright said.
“It is not very surprising that another, perhaps even larger, controlled study from the WHO would refute that data,” he added.
Bright said it is possible that larger studies, such as the WHO, show that the marginal benefit of remedesivir may be more marginal, depending on the population of drug users.
.
